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Polyphenols, Inflammation, and Cardiovascular Disease
Christy Tangney, PhD, FACN, CNS and Heather E. Rasmussen, PhD, RD
Rush University Medical Center, 1700 W Van Buren, Ste 425, Chicago, IL 60612
Abstract
Polyphenols are compounds found in foods such as tea, coffee, cocoa, olive oil, and red wine and
have been studied to determine if their intake may modify cardiovascular disease (CVD) risk.
Historically, biologic actions of polyphenols have been attributed to antioxidant activities, but
recent evidence suggests that immunomodulatory and vasodilatory properties of polyphenols may
also contribute to CVD risk reduction. These properties will be discussed, and recent
epidemiological evidence and intervention trials will be reviewed. Further identification of
polyphenols in foods and accurate assessment of exposures through measurement of biomarkers
(i.e., polyphenol metabolites) could provide the needed impetus to examine the impact of
polyphenol-rich foods on CVD intermediate outcomes (especially those signifying chronic
inflammation) and hard endpoints among high risk patients. Although we have mechanistic insight
into how polyphenols may function in CVD risk reduction, further research is needed before
definitive recommendations for consumption can be made.
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Introduction
Atherosclerosis, the pathological condition often underlying cardiovascular disease (CVD),
is a chronic inflammatory condition involved in the initiation and perpetuation of
atherosclerotic lesions, which may erode or rupture leading to clinical events such as angina,
myocardial infarction, or cerebrovascular attack. Because a poor quality diet, smoking, and
physical inactivity account for much of modifiable CVD risk, the role of diets rich in
bioactive compounds in maintaining or improving cardiovascular health is of utmost
interest. As this underlying chronic inflammation plays a key role in development and
progression of CVD, bioactive compounds with anti-inflammatory properties such as
polyphenols (PPs) is the focus of this review.
Polyphenol Classification and Food Sources
Polyphenols naturally exist in plants and plant products, including fruits, vegetables, nuts,
herbs, cocoa, and tea. Over 500 different PPs exist and are classified based on structure, with
the phenolic hydroxyl groups as the common structural feature. Differences in primary
aromatic rings, oxidation status, and functional groups delineate the individual PPs. Four
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classes of PPs comprise the majority of the PPs in foods: flavonoids, lignans, phenolic acids,
and stilbenes. Other PPs also exist in foods and are combined into a separate class (“other
PPs”) [1]. Polyphenol classes, example compounds, and their presence in select foods are
detailed in Table 1 and Fig.1. Quantification of individual PPs in these foods is not without
difficulty as individual foods often contain a wide variety of phenolic compounds, and a
combination of various techniques such as high-performance liquid chromatography, gas
chromatography, and gas chromatography-mass spectrometry are necessary for complete PP
analysis; these factors should be taken into consideration when examining PPs in foods and
the contribution of specific compounds or foods to improving CVD outcomes.
Research on the impact of PPs on inflammation and CVD has primarily focused on the
flavonoid class. Flavonoids are composed of a three-ring structure and can be subdivided
according to the presence of an oxy group at position 4, a double bond between carbon
atoms 2 and 3, or a hydroxyl group in position 3 of the C (middle) ring [2]. This class is
divided into the following primary sub-classes: flavonols, flavanones, flavan-3-ols, flavones,
anthocyanins, and isoflavones (Fig. 1). Flavonols such as kaempferol, myricetin, quercetin,
and isorhamnetin are ubiquitous in foods and are most concentrated in spices, berries and
cocoa. Flavanones are found in citrus fruits, and major compounds are naringenin and
hesperetin. Flavan-3-ols include epicatechin, gallocatechin, epigallocatechin,
epicatechingallate, epigallocatechingallate, and procyanidin (polymer). The most commonly
associated food with the flavan-3-ol compounds is both black and green tea, containing 176
mg and 171 mg/8 oz, respectively. As with most foods, green tea contains a wide variety of
PPs within various subclasses; green tea contains 14 different polyphenolic compounds
within the flavan-3-ol subclass, as well as four compounds within both the flavonol subclass
and phenolic acid class. Polyphenols in the anthocyanin class primarily consist of
anthocyanidin and anthocyanin and are prominent in foods that are red/purple in color, such
as berries and red wine. Isoflavones are unique in that they resemble estrogen in structure
and, therefore, are classified as phytoestrogens; these foods are found in soy products such
as tofu, roasted soy nuts, and miso.
Another class of polyphenols is lignans, which are characterized by their 1,4-diarylbutane
structure (Fig.1) and are found in the highest concentration (lariciresinol, matairesinol,
secoisolariciresinol) in seeds such as flax and sesame seeds (Table 1). The primary PPs in
the phenolic acid class are hydroxybenzoic acid and hydroxycinnamic acid and can be found
in appreciable quantities in coffee, walnuts, plums, and blueberries. The stilbene class is
primarily defined by resveratrol, a 1,2-diarylethene structure found in red wine that is
thought to contain anti-inflammatory properties. The final class of PPs consists of
polyphenolics unable to be categorized into the other classes (termed Other Polyphenols,
Table 1). These PPs are subcategorized into 14 subclasses, and include such compounds as
tyrosol and curcuminoids; polyphenolics within the tyrosol subclass are high in olive oil and
are thought to contribute to the health benefits seen with olive oil consumption. While
specific PPs are highest in certain foods, no food contains only one class of PPs, and it is
likely the complementary or synergistic nature of these compounds in foods is what results
in cardioprotection. Olive oil is a prime example, containing flavones, lignans, phenolic
acids (hydroxybenzoic and hydroxycinnamic acids), and an appreciable quantity of other
phenols (e.g., tyrosol, hydroxytyrosol). In addition, foods may contain other anti-
inflammatory components such as tocopherol and monounsaturated fatty acids as found in
olive oil [1], and; therefore, the anti-inflammatory properties of whole foods used in studies
(as discussed in this review) may not solely be attributed to the phenolic content. In addition,
varieties of the same food differ, with virgin olive oils (produced by direct-press/
centrifugation) containing 150-350 mg PP/kg olive oil [3] and refined olive oil not
containing an appreciable quantity of phenolic compounds. While PP content in foods is
fairly diverse and individualized to the particular food, a PP supplement often contains a
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very limited variety of compounds (e.g., resveratrol). As a result, supplementation of
individual PPs may have a different impact on CVD outcomes than consumption of whole
foods; the impact of supplements on CVD in human trials will not be discussed.
Dietary Intake
Because of the poor standardization of assays used for PP separation and quantification,
accurate quantification of PP in foods has been difficult, resulting in an incomplete resource
for PP quantities in foods. Recently, release of USDA databases including flavonoid,
isoflavone and proanthocyanidin content [4] has aided in determining PP content in foods.
Also, an additional database (Phenol Explorer [http://www.phenol-explorer.eu]) is now
available and provides the most comprehensive means by which to determine PP intake [5,
6]. PP intakes in the USA have not been well characterized, but reports for other populations
exist. The usual intake of PPs in a Finnish population has been estimated at approximately
900 mg/day [7]. Quantification of PP intake through the SU.VI.MAX study conducted in
Europe indicates that PP intake originates primarily from hydroxycinnamic acids (coffee),
proanthocyanidins (apples, cocoa products), and catechins (tea, red wine) [8]. When
categorized by foods, the greatest PP intake was from nonalcoholic beverages (coffee, tea),
fruit (apples, strawberries), and alcoholic beverages (red wine, white wine) [8]. In addition,
in the Spanish-conducted “PREvención con DIeta MEDiterránea” (PREDIMED) study,
mean PP intake was 820 mg/day, flavonoids 443 mg/day, and phenolic acids 304 mg/day,
with hydroxycinnamic acids as the highest PP consumed (276 mg/day). This PP intake was
attributed to fruit, coffee and olives/olive oil [9]. Because of the low intake of these
aforementioned foods in the USA (except for coffee), it is likely that PP intake is lower in
the USA as compared to Europe.
Bioavailability, Metabolism, and Metabolites
Not only does the wide variety of phenolic compounds in individual foods make the
objective determination of the impact of each compound on health complex, but the
understanding of PP metabolism and metabolite production is lacking. Polyphenols are
largely metabolized following ingestion, with PPs being metabolized in the stomach, small
and large intestine, and liver. Assessment of dietary PP intake has been suggested through
measurement in serum and urine metabolites, but, as indicated, it has been challenging due
to incomplete understanding of the absorption and metabolism of all PPs; the knowledge
regarding specific metabolites produced, time to appearance in biological fluids, metabolite-
intake dose relationship, and the impact of environmental factors on metabolism is necessary
in order to effectively utilize PP metabolites as biomarkers for intake [10]. Despite this,
investigators have measured metabolites as a marker of PP intake; PREDIMED used both
tyrosol and its metabolite, hydroxytyrosol, as markers of olive oil intake [11, 12]. In another
randomized crossover trial contrasting virgin olive oil versus refined olive oil intakes, the
presence of phenols in the plasma LDL fraction reflected sustained, daily ingestion of virgin
olive oil [13]. Further understanding of PP metabolism is warranted and will be critical for
determining the impact of foods on inflammation and related CVD.
Mechanisms Underlying Cardioprotection
The beneficial impact of PPs on CVD is diverse, but critical to their beneficial impact is
their role in countering chronic and acute inflammation [25,26]. Several mechanisms
explaining the anti-inflammatory activity of PPs (especially the flavonoids) will be
described, including antioxidant and radical scavenging activities and regulation of cellular
activities of inflammation-related cells and their molecular targets, including improvements
in endothelial structure and function (Table 2).
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Antioxidant and Radical Scavenging Activities
Many reports have described the antioxidant properties of PPs, a function largely
attributable to their phenolic hydroxy groups [14]. Antioxidant capacity is mediated by the
ability to scavenge free oxygen and nitrogen species, abrogating the pro-inflammatory
activity of reactive oxygen species (ROS)-generating enzymes such as cyclooxygenase
(COX), lipoxygenase (LOX), and inducible nitric oxide synthase (iNOS). Polyphenols also
contribute to the antioxidant defense of endothelial cells by reducing NADPH oxidase
expression and its activity directly. Finally, PPs stimulate antioxidant activities of other
enzymes such as catalase [15]. Production of ROS such as the potent LDL oxidant
peroxynitrite from superoxide and nitric oxide (NO) in the vessel lumen is a primary trigger
for endothelial injury, an event that drives a marked inflammatory response [16].
The evidence for these antioxidant properties is largely based on in vitro models. For
example, in vitro, resveratrol, the stilbene found in red wine, and other phenols protect LDL
against peroxynitrite-mediated oxidation [16]. Resveratrol also has been shown to up-
regulate thioredoxin, a cellular protein reductase responsible for maintenance of redox
environment within myocytes. Resveratrol protects against oxidative stress not solely
because of a direct antioxidant capacity, but also by up-regulating other endogenous
antioxidant pathways [17]; resveratrol enhances the expression of superoxide dismutase,
catalase, and glutathione peroxidase in cardiac and aortic smooth muscle cells [18, 19].
Further work suggests that these events result from changes in transcriptional activity of
nuclear transcription factor erythroid-2 related factor-2 (Nrf2) and upregulation of the
expression of several Nrf2 genes---NAD(P)H:quinone oxidoreductase I, γ-glutamylcysteine
synthetase, and heme oxygenase [20]. Changes in the expression of these genes along with
those for thioredoxin may be responsible for the purported antioxidant activity of resveratrol
and epicatechin. Other phenolic compounds may function as antioxidants. Quercetin reduces
LDL oxidation at physiologic concentrations through inhibition of myeloperoxidase [21].
Other flavonoids (specifically, fisetin and quercetin) modulate macrophage-stimulated LDL
oxidation, possibly through inhibition of generation of lipid hydroperoxides.
Proanthocyanidins have a concentration-dependent scavenging ability and are more potent
than vitamins C or E and resveratrol [22].
There are few large trials that demonstrate the benefits of PP exposure as has been seen in in
vitro studies. To date, the best examples are derived from the Spanish primary prevention
trial PREDIMED. In a substudy, Covas and colleagues examined the impact of virgin olive
oil, refined olive oil, and a mixture of both in two equal parts in a crossover trial of three, 3-
week periods [23]. Virgin olive oil had the greatest benefit with respect to favorable lipid
changes and reductions in oxidative stress markers. Plasma oxidized LDL concentrations,
those of conjugated dienes and hydroxyl fatty acids, decreased in parallel with higher
phenolic content. However, the recent International Life Sciences Institute Europe working
group questioned the biologic relevance of the antioxidant effects of PPs for cardiovascular
health on the grounds that there is limited evidence for the impact of these dietary PPs on
circulating biomarkers such as F2-isoprostanes, oxidized LDL, and conjugated dienes [24].
In addition, circulating levels of PPs are low in comparison to those of other antioxidants
such as vitamin C, urate, and tocopherols. This group stated that the evidence for the
antioxidant mechanism of dietary PPs in cardioprotection continues to accumulate but is still
not yet conclusive [24].
Inflammatory Mechanisms
Many of the effects that dietary PPs exhibit are likely through impacts on transcriptional
networks or signaling cascades that modulate gene expression, promoting anti-inflammatory
mediators, and NO production. These counter the adhesive nature of the vascular-immune
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cellular interplay, thereby abrogating or limiting endothelial dysfunction. Dietary PPs act on
both of these processes (inflammation and endothelial dysfunction) implicated in the
development of CVD by in part altering the recruitment or “homing” of inflammatory cells
from the circulation and down-regulating the production of adhesion molecules by the
endothelium, thereby hindering cellular migration into the subendothelial space and
reducing atherosclerotic plaque formation. In addition, foods rich in PPs, in particular,
flavonoids, have been shown to 1) modify endothelial formation of NO and EDHF, as
shown in isolated blood vessels, and 2) improve endothelial function as shown in
experimental models of CVD and with functional tests such as flow-mediated vasodilation
(FMD) in humans.
Soluble pro-inflammatory molecules such as tumor necrosis factor α (TNFα), interleukin-6
(IL-6), and C-reactive protein (CRP) secreted by circulating immune cells interact with
adhesion markers expressed on T lymphocytes (CD49d) and monocytes (CD40); the latter is
critical to leucocyte homing. These circulating cells interact with molecules produced by the
endothelium, such as E-selectin and the intercellular adhesion molecule-1 (ICAM-1). In
vitro studies demonstrate that resveratrol moderates the overexpression of adhesion
molecules (VCAM-1 and ICAM-1) through an inhibition of the NF-κB pathway in
endothelial cells [28]. Resveratrol also abrogates the angiotensin II-induced adhesion of
leukocytes by reducing cellular adhesion molecule expression and reducing serum monocyte
chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein 1α (MIP-1α)
[29]. This PP also has been shown to reduce pro-inflammatory cytokine secretion (IL-6 and
TNFα) through downregulation of the NF-κB pathway [30] as well as promote adiponectin
expression and release from human adipose tissue. The anti-inflammatory properties of
quercetin are also similar to that observed for resveratrol in that these PP target signaling
pathways are related to the NF-κB pathway, thereby decreasing mRNA and protein levels of
TNFα, IL-6, MIP1α and P-selectin [32]. The interactions between circulating inflammatory
cells and endothelial cells along the luminal surface of blood vessels modulate vascular
function, in part by changes in release of nitric oxide (NO), endothelium derived
hyperpolarizing factor (EDHF), and prostacyclin. Endothelial dysfunction is often due to an
imbalance between vasorelaxation and vasoconstriction. The latter results from reduced
availability of NO and EDHF and increased NADPH oxidase-dependent oxidative stress
with the resultant formation of vasoconstrictive factors (such as endothelin-1) in the arterial
wall [27]. Quercetin possesses vasodilatory properties through a reduction in endothelin-1
mRNA expression [31]. Delphinidin, quercetin and resveratrol, as well as PP extracts from
red wine, activate endothelial nitric oxide synthase (eNOS), the enzyme responsible for NO
production and resultant endothelium-dependent vasorelaxation [33]. The role PPs have on
eNOS is suggestive of an intracellular redox-sensitive mechanism [34-36]. These PPs
(resveratrol, quercetin, and delphinidin) may also activate eNOS through changes in calcium
signaling and estrogen receptor function.
Direct translation of the impact of individual compounds in cell culture systems or animal
models into human application is difficult because of multiple PPs in individual foods and
overall dietary patterns. Thus, clinical studies utilizing foods or beverages provide a more
realistic assessment of clinical impact. In a randomized crossover trial designed to examine
the alcohol-independent effects of phenolic compounds of red wine on expression of soluble
and leukocyte adhesion molecules and proinflammatory cytokines, 67 high CV risk male
subjects received each of three treatments in random order: 30 g red wine, 30 g
dealcoholized red wine or 30 g gin (containing no PP) daily for 30 days [37]. The red wine
and dealcoholized red wine beverage treatments decreased serum concentrations of ICAM-I
and IL-6 as well as the expression of T-lymphocyte and monocyte markers when compared
to gin, indicating that the PP fraction was responsible for reduced inflammation. On the
other hand, both alcohol and PPs may influence atherosclerosis as evidenced by
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downregulation of CD40a, CD40L, and MCP-1, VCAM-1, and E-selectin levels only in the
red wine group.
Polyphenols in olive oils and nuts as part of a Mediterranean diet (MedDiet) have also been
shown to affect changes in adhesion molecules and pro-inflammatory cytokines in over 772
subjects on a 3-month long dietary intervention that was part of the PREDIMED trial. This
three-arm, parallel-group trial tested two Mediterranean dietary interventions on
cardiovascular endpoints through the daily consumption of a MedDiet supplemented with
either virgin olive oil (1L per week per family) or mixed nuts (30 g per week per individual).
The control group consumed a low-fat diet devoid of these foods. The MedDiet treatment
with PP-rich olive oil reduced circulating CRP levels, while both MedDiet treatments (virgin
olive oil; nuts) lowered IL-6, ICAM-1, and VCAM-1[38]. In another PREDIMED substudy
of 112 subjects, IL-6, ICAM-1, CD49d, and CD40 were reduced following 3 months of both
the MedDiet interventions in comparison to the low fat diet [39], while VCAM-1 and CRP
were reduced by the virgin olive oil treatment only. Other groups have supported these
findings; virgin olive oil lowered plasma CRP and IL-6 concentrations and downregulated
expression of VCAM-1, ICAM-1 and E-selectin in the endothelium, an effect attributable to
the phenolic extract from olive oil [40]. Further work by these researchers suggests olive oil
phenolic extract, in particular oleuropein aglycone, disrupts TNFα signaling [41] and, thus,
reduces the self-perpetuating inflammatory process in the vascular wall that ultimately leads
to plaque formation and vulnerability.
Fitzpatrick and coworkers were among the first to show that select foods and extracts of PP-
rich foods (i.e., wines, grape juice, grape skin extracts) induce endothelium relaxation in
aortic rings [42]. Because such foods cause endothelium-dependent relaxation that is
abrogated by competitive inhibitors of eNOS and guanylcyclase; it may be inferred that
these PPs modify NO formation; evidence suggests that EDHF is involved as well [35, 43].
In addition, endothelium-dependent relaxation of porcine coronary artery rings induced by
red wine PPs has been observed at concentrations of 3 μg/mL or higher [35], which
approximates the plasma concentrations of PP monomers following intake of 100 mL red
wine [44].
Functional changes in the endothelium as a result of this inflammatory process have been
assessed by flow mediated vasodilation (FMD) in subjects [45]. At doses approximating two
glasses of red wine [46] or 46 g of dark chocolate every day for 2 weeks [47], FMD
improved in healthy subjects. In a recent meta-analysis, ingestion of chocolate or cocoa
flavan-3-ols was associated with a 3.2 % increase in FMD (95 % CI: 2.0, 4.3; 11 studies,
373 participants, I2=84 %) for acute effects (within 2 hours of ingestion), and after chronic
intake, FMD increased by 1.3% (95% CI: 1.0, 1.7; 11 studies, 382 participants, I2=0 %)
[48]. Among those with coronary heart disease, chronic black tea consumption [49] or red
grape extracts [50] was also shown to improve FMD. Based on a recent meta-analysis,
researchers found that each 1 % increase in FMD was associated with a 13 % reduction in
risk for CV events (95 % CI: 0.83, 0.91) [51].
Impact on Cardiovascular Disease Endpoints
Evidence from cross-sectional and prospective cohort studies suggests that intakes of certain
PPs (flavonoid classes, in particular) reduce CVD risk. In a recent review of 12 cohort
studies, a decrease in age-adjusted CHD mortality was observed with increasing intakes of
flavonoids [52]. Four USA cohorts were included: the Health Professionals Follow-up study,
Iowa Women’s Health study, the Women’s Health study, and the Nurses’ Health Study
(NHS). In the NHS cohort, the highest quintile of (>63 mg/d) flavanone intake was
associated with reduced ischemic strokes (RR=0.81, 95 % CI, 0.66, 0.99, p=0.04) [53]. In
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the Cancer Prevention Study II Nutrition Cohort, those with the highest total flavonoid
intakes (highest quintile, median=512.5 mg/d) had 18 % fewer deaths from cardiovascular
disease (multivariate RR=0.82, 95 % CI, 0.73, 0.92, p=0.01) compared to the lowest
flavonoid intakes (median=94.5 mg/d). Similar cardiovascular risk reductions were noted for
five flavonoid subclasses: anthocyanidins, flavan-3-ols, flavones, flavonols, and
proanthocyanidins. No change is risk was seen with flavanone intake. Among men, fewer
deaths from stroke were associated with flavonoid intakes (RR=0.63, 95 % CI, 0.44, 0.89, p
trend=0.04) as compared to no impact of flavonoids on deaths from ischemic heart disease
(RR=0.90, 95 %CI, 0.72, 1.13). As in prior cohort studies, intakes were assessed by the 152-
item FFQ, and nutrient data were derived from three USDA databases [54]. In yet another
meta-analysis that included six cohort studies in three countries, flavonol intakes (>21mg/d)
reduced incidence of strokes by 20 % (pooled RR=0.80 (95 % CI: 0.65, 0.98)[55]. There is
little evidence for cardioprotection with higher isoflavone or lignin intake. The observed risk
reduction in incident strokes is consistent with risk reductions observed for hypertension.
Risk of incident hypertension was reduced by 5-8 % among those with higher intakes (>16
mg/d) of anthocyanins (mostly blueberries and strawberries) [56]. The authors suggest that
some of the structural similarities, the B-ring hydroxylation and methyoxylation pattern,
may explain the vasodilatory properties of these compounds. In addition, PP in olive oil
have also been associated with better CVD outcomes, in particular, stroke. The Three-City
study in French adults reported a 41 % reduction in stroke incidence among those using
olive oil for cooking and salad dressing as compared to those who had never used olive oil
(RR=0.59, 95 % CI: 6, 63, p=0.03) after 5.3 years of follow-up [57].
Particularly key to an evaluation of the evidence from observational studies is dietary
assessment of PP intakes. All too often only a limited number of PPs are considered in food
analyses used in food composition databases [58, 59]. Some groups have relied on the recent
USDA database which contains 38 flavonoid aglycones [4, 60, 61], but others who have
examined cardiovascular endpoints and dietary flavonoids are based on analyses derived
from older, less complete USDA databases. More recently, a new Phenol-Explorer database
[5] mentioned previously is being adopted by more research groups [24, 62]. However, food
composition data for many PPs (in particular phenolic acid content) are still incomplete.
While evidence continues to accumulate from observational and other studies, one cannot
forget the ongoing primary prevention trial, PREDIMED, of 7,447 participants (55-80 years,
57 % women) in Spain. At baseline, trial participants had to be free of cardiovascular
disease, but could have type 2 diabetes or ≥3 cardiovascular risk factors (www.predimed.es,
www.predimed.org). The two MedDiet interventions (MedDiet supplemented with either
olive oil or nuts) reflect consumption of a broader spectrum of PPs---the contribution of not
only flavonoids, but also phenolic acids and some lignans. Lower rates of incident diabetes
[63], metabolic syndrome [64], and hypertension [65] have been reported for those assigned
to the MedDiet with olive oil or nuts when compared to those on the low-fat diet
intervention. The reductions in incident diabetes were particularly compelling; the
multivariable adjusted hazard ratios were 0.49 (95 % CI: 0.25, 0.97, p=0.047) and 0.48 (95
% CI: 0.24, 0.96, p= 0.053) in the MedDiet supplemented with olive oil and nut groups,
respectively, compared with the control group. Diabetes risk reduction occurred in the
absence of significant changes in body weight or physical activity. While these findings
clearly identify a MedDiet as beneficial for diabetes, an important risk equivalent for CVD,
the primary outcomes are not yet published, and we do not yet know if CVD incidence will
be reduced in those consuming a dietary pattern high in PPs (MedDiet). To the best of these
authors’ knowledge, there are no other large clinical trials in which the effects of PP intakes
on cardiovascular morbidity or mortality have been investigated.
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Conclusion & Future Directions
There are several challenges to our current understanding of the role that PPs play in the
inflammatory process and related inflammatory diseases. These include: 1) a paucity of
information on the content of several PP compounds in foods, 2) the use of incomplete and
outdated databases by researchers, 3) a limited number of studies regarding the utility,
kinetics, choice of fluid or tissue, and choice of assay for biomarkers of PP intake, and 4) the
dearth of adequately powered food-based trials in the USA similar to PREDIMED.
However, recent mechanistic insights provide support for the potential role of PPs in the
inflammatory process including reduced ROS, cytokine expression, and endothelial
inflammatory markers, as well as increased NO production. However, one cannot
extrapolate the benefits of PP intake solely through examination of these mechanisms.
Intervention trials are needed using PP-rich foods to assess whether typical intakes of such
provided foods will result in cardioprotection. Efforts similar to what PREDIMED
investigators have fostered might be fruitful here in the USA. To the best of our knowledge,
no such long-term food based trial with cardiovascular hard endpoints has been conducted in
the USA. As in PREDIMED, several translational, mechanistic studies as well as short-term
clinical studies with immediate CV markers (such as pro-inflammatory adhesion markers of
measures of endothelial function (i.e., FMD) could be planned within the bigger trial. In
addition, potential biomarkers of dietary exposures (i.e., plasma or urinary tyrosol, etc.)
could be evaluated in this trial in high CVD risk American adults. Finally, coordination of
PP determinations in foods is needed at an international level so food composition data can
be shared for both Phenol Explorer and USDA databases.
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Figure 1.
Major classes of dietary polyphenols and example chemical structures. The Figure does not
include polyphenols that are categorized as “other polyphenols.” Adapted from Spencer et
al. [10].
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Table 2
Major anti-inflammatory mechanisms and example phenolic compounds that elicit these effects
1
Antioxidant Activity
Inhibition of Reactive Oxygen and Nitrogen Species
    Direct scavenging of peroxynitrite, hydroxyl radicals, superoxide anion, nitric oxide
Modifies signaling cascades and transcriptional networks 
2
Inhibition of Pro-oxidant Enzymes
  Suppress activity and expression of endothelial NAPDH oxidase, lipoxygenase, myeloperoxidase,
  cyclooxygenase-2, phospholipase, inducible nitric oxide synthase (quercetin, apigenin, kaempferol)
Blocks NFκB signaling and expression (resveratrol, quercetin)
  Downregulates TNFα, IL1β, IL-6 synthesis (resveratrol, olive oil)
  Reduces expression of VCAM-1 and ICAM-1 (resveratrol, olive oil)
  Reduces MCP-1, MIP-1α expression (quercetin, resveratrol)
Upregulation of NrF2 genes and thioredoxin to maintain redox state (epicatechin, tea)
Reduces adhesion of immune cells (T lymphocytes, monocytes) to endothelium
  Suppression of adhesion markers on endothelium, vascular smooth muscle cells: CD40. VCAM,
ICAM, E-selectin, P-selectin (red wine, nuts, olive oil)
  Inhibit expression of MMP1 (resveratrol)
Counters Endothelial dysfunction
Downregulates endothelial contractility factor, decreases endothelin-1 expression and release (resveratrol)
Increases nitric oxide availability because of increased activity of endothelial nitric oxide synthase
(delphinidin, quercetin, resveratrol, red wine)
Upregulates endothelial derived hyperpolarizing factor (red wine, grapes)
1
MAPK, Mitogen-activated protein kinase; JNK, Jun N-terminal kinase; NADPH, nicotinamide adenine dinucleotide phosphate; NF-kB, nuclear
factor-kappa B; TNF-α, tumor necrosis factor-α, IL-1B, interleukin-1 beta; IL-6, interleukin 6; VCAM, vascular cell adhesion molecule; ICAM,
intercellular adhesion molecule; MCP-1, monocyte chemoattractant protein-1; MIP, macrophage inflammatory protein; CD40, Cluster of
differentiation 40; Nrf2, nuclear transcription factor erythroid-2 related factor- 2; MMP1, metalloproteinase I.
2
Modulates tyrosine and serine-threonine protein kinases (MAPKs [i.e., p38, JNK]) involved in signal transduction and cell activation
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